Bacillus Calmette-Guérin treatment and vesicorenal reflux.
14 patients with radiologically documented vesicorenal reflux (5 bilateral, 7 unilateral, 2 unilateral double-J stents) received intravesical immunotherapy with bacillus Calmette-Guérin (BCG) after treatment of their superficial urothelial tumors. 1 patient with a double-J stent suffered a highly febrile attack following obstruction of the indwelling ureteral catheter. The other patients tolerated 1 or 2 (6 of 14 patients) courses of BCG without an increase in side effects. Topical intravesical therapy with BCG in patients with vesicorenal reflux seems to be indicated in view of the multicentricity of urothelial carcinoma and can be performed without an increased risk of complications.
Böhle
A
A
Department of Urology, Medical University of Lübeck, FRG.
Schüller
J
J
Knipper
A
A
Hofstetter
A
A
D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000150:complications*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D015607:Stents; D001745:Urinary Bladder Diseases / Q000150:complications*; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D001500:BCG Vaccine